Research Hub
Written and maintained by the AVERON Research Desk · Last reviewed September 2026
This is the AVERON Research Desk: a reference library on the compounds in our catalog and the science around them. It exists because this market is full of confident claims and very few sources. We try to do the opposite. Every page here says what a compound is, what published research actually shows, what it does not show, and where the evidence is thin. Every claim that matters is linked to a primary source, so you can check it rather than take our word for it.
Why we built it
Most sellers of research peptides describe their products in the language of results. We think that is the wrong way round. A compound that has only been studied in rats should say so. A compound that is an approved medicine in one country for one condition should say exactly that, and not imply it is approved for anything else. A lab report proves some things and not others, and the difference matters. These pages are where we write all of that down.
What you will find here
The compound encyclopedia. One page per compound we carry. Each page opens with an evidence level so you can see at a glance how much is known, then covers what the compound is, what it has been studied for, what the research found, what it does not do, adverse effects reported in studies, and its regulatory and anti-doping status. Start at the Compound Encyclopedia.
Lab reports and verification. How to read a certificate of analysis, what HPLC and mass spectrometry measure, what a lab report cannot tell you, and how independent testing by Janoshik Analytical works. Every batch we sell has a report hosted on the laboratory's own server, which you can look up yourself.
Fundamentals and laboratory handling. What peptides are, what lyophilized powder is, the arithmetic of reconstitution, bacteriostatic versus sterile water, units, storage in a hot climate, and how blends work.
Comparisons. Side-by-side notes on the compounds people most often confuse with each other.
What you will not find here
No dosing, no injection instructions, no protocols for people, and no promises about results. That is a deliberate choice. We are a registered distributor, not a clinic. We do not employ doctors and we do not give medical advice. These pages describe research and regulation, and stop there.
How we decide what a study shows
Every compound page carries one of four evidence levels: Approved Medicine, Human Trial Data, Early Human Data, or Preclinical Only. We assign them from published sources, favour primary sources over summaries, and say so when sources disagree. A high level for one condition does not transfer to another use.
Browse the research
Every compound we carry, with an evidence level and its regulatory status.
Plain definitions of 55 peptide, laboratory and regulatory terms.
Look up the independent Janoshik lab report for every AVERON batch.
A line-by-line guide to a peptide certificate of analysis.
Independent testing, matching batch codes, and the red flags to avoid.
The limits of a standard lab report, including the limits of ours.
What a purity percentage measures, and what it leaves out.
How molecular weight confirms identity, and why that differs from purity.
How the laboratory tests peptides and how public verification works.
What the label means, and why we take it literally.
The four evidence levels, how we assign them and what they do not mean.
What peptides are, how they are made and why they are studied.
Same building blocks, different size — and why that matters.
Why peptides arrive as freeze-dried powder, and what is in it.
The concentration arithmetic and the clean handling method.
One ingredient separates them, and it decides multi-use safety.
Storing sealed powder and solutions in heat and humidity.
What changes once a vial is mixed, and the 28-day reference.
A unit is a volume, not an amount — the scale and the arithmetic.
Two ways to measure small volumes, compared as tools.
What each unit measures, and why they cannot be swapped.
How multi-compound vials are made, measured and tested.
The law first, then keeping vials stable on the journey.
An experimental triple agonist with published phase 2 trial data.
A dual GIP and GLP-1 agonist approved as Mounjaro and Zepbound.
The GLP-1 agonist behind Ozempic and Wegovy, with the longest record.
A mitochondrial-derived peptide studied in mice for metabolism.
A GHRH analogue approved for one narrow, often misrepresented use.
A small-molecule NNMT inhibitor studied in mice, not a peptide.
A coenzyme central to energy metabolism, with thin human evidence.